ArticleInternational journal of clinical and experimental pathology2017
The diagnostic and prognostic value of serum miR-206 in colorectal cancer.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis.BioMed research international · 2020Pooled it
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.Diabetes & metabolism journal · 2023Trial
- Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.International journal of molecular sciences · 2024Review
- Downregulation of Serum miR-133b and miR-206 Associate with Clinical Outcomes of Progression as Monitoring Biomarkers for Metastasis Colorectal Cancer Patients.MicroRNA (Shariqah, United Arab Emirates) · 2024Article
- MicroRNA-206 inhibits the proliferation, migration and invasion of colorectal cancer cells by regulating the c-Met/AKT/GSK-3β pathway.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating microRNAs (miRNAs) are emerging as promising biomarkers for colorectal cancer (CRC). In this study, we sought to examine the diagnostic and prognostic role of serum miR-206 in CRC. A total of 73 CRC cases and 45 healthy control subjects were enrolled in this study. Quantitative reverse transcription PCR (qRT-PCR) was used to measure the relative serum miR-206 levels. Serum miR-206 levels were significantly decreased in CRC patients than normal controls. In addition, serum miR-206 demonstrated good diagnostic performance for discriminating CRC patients from healthy controls. miR-206 levels were increased in the blood samples of CRC patients who received surgery treatment. Moreover, serum miR-206 expression was closely associated with TNM stage and lymph node metastasis. CRC patients with low miR-206 level suffered more unfavorable overall survival and disease free survival compared to those with high miR-206 level. Furthermore, serum miR-206 was confirmed to be an independent prognostic indicator for CRC. In summary, serum miR-206 might be a promising biomarker for the diagnosis and prognosis of CRC.
Indexed as
Identifiers
31966596PMC6965214W3009226610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.